Summary
One hundred nineteen cases of advanced adenocarcinoma of the lung were divided into well differentiated adenocarcinoma (72 cases) and poorly differentiated adenocarcinoma (47 cases) histologically and/or cytologically. The median survival of 72 cases of well differentiated adenocarcinoma (7.9 months) was significantly (P<0.025) longer than that of poorly differentiated adenocarcinoma (4.9 months) irrespective of stage, difference in treatment regimen, or response to treatment. In 9 evaluable cases, the objective response rate to chemotherapy was 25% (6/24) in poorly differentiated adenocarcinoma and 11.3% (8/71) in well differentiated adenocarcinoma, respectively. In 45 patients who received a combination of chemotherapy and radiotherapy, the median survival of 22 well differntiated adenocarcinomas (11.8 months) was significantly (P<0.05) longer than that of 23 poorly differentiated adenocarcinomas (5.6 months). The same tendency was observed in 74 patients who received chemotherapy alone. Analysis based on the grade of differentiation is essential for the accurate assessment of the efficacy of treatment in adenocarcinomas of the lung.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bergsagel DE, Jenkins RDT, Pringel JF (1972) Lung cancer: Clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30:621–627
Bitran JD, Dresser RK, DeMesser T, Shapiro CM, Billings A, Rubenstein L, Evans R, Colman M, Griem M, Golomb HM (1978) Combined modality therapy for stage III non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62:327–332
Brittell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S (1978) cis-dichlorodiammineplatinum (II) alone follwed by adrinamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophophamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62:1207–1210
Issel BF, Valdivieso M, Body GP (1978) Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with futraful, adriamycin, and cis-dichlorodiammine-platinum. Cancer Treat Rep 62:1089–1091
Koketsu H, Subtype of adenocarcinoma classified by cytology. (Personal communication)
Livingstone RB, Heilburn LH, Thing pen T, Coltman CA, Haas C (1978) Adriamycin and chlorambucil in the treatment of extensive, non-small cell carcinoma of the lung: A Southwest Oncology Group pilot study. Cancer Treat Rep 62:1215–1217
Mathew MJ (1973) Morphologic classification of bronchogenic carcinoma. Cancer Chemother Rep 4:229–302
Matthew MJ (1974) Morphology of lung cancer. Seminars in Oncol 1:175–182
Niitani H, Suzuki A, Shimoyama M, Kimura K (1964) Effect of mitomycin C injection of lysosomal enzyme activities of Yoshida ascites Sarcoma. Gann 55:447–454
Niitani H, Suzuki A, Taniguchi T, Saijo N, Kawase I, Kimura K (1974) Effect of combination treatment with mitomycin C and lysosome labilizers on nodular pulmonary metastases. Gann 65:403–409
Samson MK, Comis RL, Baker LH, Grinsberg S, Fraile RJ, Crooke ST (1978) Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62:163–165
Selawry OS (1973) Monochemotherapy of bronchogenic carcinoma with special reference to cell type. Cancer Chemother Rep Part 3, 4:177–188
Selawry OS (1974) The role of chemotherapy in the treatment of lung cancer. Seminars in Oncol 1:259–273
Vogelzang NJ, Bonomi PD, Rossof AH, Wolter J (1978) Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62:1595–1597
Author information
Authors and Affiliations
Additional information
Supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare
Rights and permissions
About this article
Cite this article
Saijo, N., Niitani, H., Tominaga, K. et al. Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung. J Cancer Res Clin Oncol 97, 71–79 (1980). https://doi.org/10.1007/BF00411280
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00411280